"Muscarinic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
| Descriptor ID |
D018727
|
| MeSH Number(s) |
D27.505.519.625.120.200.500 D27.505.696.577.120.200.500
|
| Concept/Terms |
Muscarinic Antagonists- Muscarinic Antagonists
- Antagonists, Muscarinic
- Antimuscarinics
- Antimuscarinic Agents
- Agents, Antimuscarinic
- Cholinergic Muscarinic Antagonists
- Antagonists, Cholinergic Muscarinic
- Muscarinic Antagonists, Cholinergic
|
Below are MeSH descriptors whose meaning is more general than "Muscarinic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Muscarinic Antagonists".
This graph shows the total number of publications written about "Muscarinic Antagonists" by people in this website by year, and whether "Muscarinic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 7 | 0 | 7 |
| 2010 | 6 | 1 | 7 |
| 2011 | 3 | 3 | 6 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Muscarinic Antagonists" by people in Profiles.
-
Biomarkers to Predict Response to Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists in Adolescents and Adults with Mild Persistent Asthma. Ann Am Thorac Soc. 2022 03; 19(3):372-380.
-
Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 05 01; 201(9):e56-e69.
-
Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. Ann Am Thorac Soc. 2019 02; 16(2):200-208.
-
Pharmacological manipulation of the olfactory bulb modulates beta oscillations: testing model predictions. J Neurophysiol. 2018 09 01; 120(3):1090-1106.
-
Time to Converge FDA Decisions and Evidence Syntheses for Long-Acting Muscarinic Antagonists and SMART in Guidelines for the Treatment of Asthma. JAMA. 2018 04 10; 319(14):1441-1443.
-
Severe peri-ictal respiratory dysfunction is common in Dravet syndrome. J Clin Invest. 2018 03 01; 128(3):1141-1153.
-
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017 09; 50(3).
-
Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs. J Biol Chem. 2016 Jun 17; 291(25):13132-46.
-
The molecular basis of oligomeric organization of the human M3 muscarinic acetylcholine receptor. Mol Pharmacol. 2015 Jun; 87(6):936-53.
-
Muscarinic acetylcholine receptor activation blocks long-term potentiation at cerebellar parallel fiber-Purkinje cell synapses via cannabinoid signaling. Proc Natl Acad Sci U S A. 2013 Jul 02; 110(27):11181-6.